Passage Bio (PASG) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Downgraded | Outperform → Neutral | $8.00 from $32.00 | Apr 21, 2026 |
| Oppenheimer | Maintained | Outperform | $15.00 from $30.00 | Apr 21, 2026 |
| Chardan Capital | Downgraded | Buy → Neutral | $7.00 from $21.00 | Apr 21, 2026 |
| TD Cowen | Downgraded | Buy → Hold | — | Apr 21, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $30.00 | Mar 31, 2026 |
| Canaccord Genuity | Maintained | Buy | $23.00 from $67.00 | Mar 4, 2026 |
| Chardan Capital | Maintained | Buy | $21.00 from $6.00 | Nov 12, 2025 |
| Guggenheim | Maintained | Buy | $10.00 from $40.00 | Aug 14, 2025 |
| Canaccord Genuity | Maintained | Buy | $67.00 from $260.00 | Aug 14, 2025 |
| Wedbush | Maintained | Outperform | $40.00 from $3.00 | Aug 13, 2025 |
| Chardan Capital | Maintained | Buy | $6.00 | Jun 24, 2025 |
| Chardan Capital | Maintained | Buy | $6.00 from $7.00 | Mar 4, 2025 |
| Wedbush | Initiated Coverage | Outperform | $4.00 | Nov 29, 2024 |
| Canaccord Genuity | Maintained | Buy | $13.00 | Nov 14, 2024 |
| Chardan Capital | Maintained | Buy | $7.00 | Nov 14, 2024 |
| Rodman & Renshaw | Initiated Coverage | Buy | $7.00 | Sep 3, 2024 |
| Canaccord Genuity | Maintained | Buy | $13.00 from $14.00 | May 15, 2024 |
| Canaccord Genuity | Maintained | Buy | $14.00 | Mar 5, 2024 |
| Raymond James | Maintained | Outperform | $5.00 from $9.00 | Nov 14, 2023 |
| Chardan Capital | Maintained | Buy | $9.00 from $11.00 | Aug 8, 2023 |
Frequently asked questions
Is PASG a buy, sell, or hold?
Analysts covering Passage Bio currently average a Hold rating: 0 buy, 1 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on PASG?
On Apr 21, 2026, Wedbush downgraded Passage Bio to Neutral with a price target of $8.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.